The Founding Chair of Bellberry’s Board of Directors, Fraser Bell, has paid tribute to retiring Board member Professor Emeritus Lloyd Sansom AO for his 12 years on the Board.
“Once in a while a Board gets to work with a person of enormous integrity, wisdom, humility, humour and a capacity to roll up his sleeves and get things done,” said Mr Bell.
“Bellberry has had just that opportunity with Lloyd Sansom. Our company made huge strides forward due to Lloyd’s vision with our Thought Leadership Program in particular.
“While that is the obvious legacy, each of his fellow Board members and the executive team are better off for having shared the journey with Lloyd,” said Mr Bell.
Professor Sansom was Professor of Pharmacy as well as Head of the School of Pharmacy and Medical Sciences at the University of South Australia. In 2004 his contribution to the University was recognised with the naming of the Sansom Institute for Health Research.
He was also the Chair of the Australian Pharmaceutical Advisory Council from 1991-2000 and Chair of the Pharmaceutical Benefits Advisory Committee from 2001 to 2012.
Professor Sansom said it’s been a privilege to watch Bellberry grow over the last 12 years.
“Bellberry is a company that provides a high-quality service, but it does more than that. It is contributing to the advancement of the discipline of clinical trial research in this country and beyond,” said Professor Sansom.
Professor Andrew Wilson AO, who has recently retired as chair of the Pharmaceutical Benefits Advisory Committee will be joining the Bellberry Board.
Board Chair Fraser Bell has welcomed Professor Wilson’ appointment, “Andrew’s expertise and insights are well known to us and we are looking forward to working with him”.
Bellberry is Australia’s largest reviewer of human research reviewing more than 40% of CTN Clinical Trials in Australia. It’s a national, independent, not-for-profit organsiation focused on improving the welfare of human research participants and the quality, efficiency and effectiveness of medical research through its HREC reviews and philanthropic activities.
For media queries contact [email protected] or call 0488 995 868
